$ AAPL

$ ABBV

$ ABNB

$ ACGL

$ ADI

$ ADM

$ ADP

$ ADSK

$ AEE

$ AEP

$ AES

$ AFL

$ AIG

$ AIZ

$ AJG

$ AKAM

$ ALB

$ ALGN

$ ALL

$ AMAT

$ AMCR

$ AMD

$ AME

$ AMGN

$ AMP

$ AMT

$ AMZN

$ ANET

$ AOS

$ APA

$ APD

$ APO

$ APTV

$ ARE

$ ATO

$ AVB

$ AWK

$ AXON

$ BA

$ BALL

$ BAX

$ BBY

$ BDX

$ BEN

$ BG

$ BIIB

$ BKNG

$ BLDR

$ BMY

$ BR

$ BRO

$ BXP

$ CAG

$ CAH

$ CARR

$ CAT

$ CBOE

$ CBRE

$ CCL

$ CDNS

$ CDW

$ CEG

$ CF

$ CHD

$ CHRW

$ CI

$ CINF

$ CL

$ CLX

$ CMCSA

$ CMG

$ CMI

$ CMS

$ COIN

$ COO

$ COP

$ COR

$ CPAY

$ CPT

$ CRL

$ CRWD

$ CSCO

$ CTRA

$ CTSH

$ CTVA

$ CVS

$ CVX

$ CZR

$ DAL

$ DASH

$ DAY

$ DD

$ DDOG

$ DE

$ DELL

$ DG

$ DGX

$ DIS

$ DOC

Cognizant (CTSH) posts strong Q2 2025 results and raises guidance on AI momentum and large deals, but faces margin pressures and significant litigation risk.

# Cognizant Delivers Strong Q2 2025 Beat, Raises Guidance Amid AI Momentum and Litigation Overhang

---

## Executive Summary

- **Cognizant Technology Solutions (CTSH) delivered a robust Q2 2025, beating on both revenue and EPS, with revenue of $5.25B (+8.1% YoY) and GAAP/adjusted EPS of $1.31 (up 15%/12% YoY, respectively).** The company’s top-line outperformance was driven by significant volume expansion, highlighted by an 18% YoY increase in bookings and two mega deals exceeding $1B each.
- **Earnings quality was solid, with GAAP operating margin at 15.6% (up 100 bps YoY),** though a sequential decline from Q1 (16.7%) signals emerging cost pressures. Adjusted margins improved modestly both YoY and sequentially, reflecting disciplined cost management despite sector headwinds.
- **Management struck a bullish tone, raising full-year revenue and EPS guidance** and emphasizing the strategic impact of AI-led initiatives, large deal momentum, and the Belcan acquisition. However, they acknowledged sequential margin compression and flagged cybersecurity as a growing risk.
- **Key risks include a $380M Clorox lawsuit related to a 2023 cyberattack, sequential margin contraction, and rising short interest (5.55% of float),** all of which could weigh on future profitability and sentiment. Conversely, the company’s AI strategy, large deal wins, and enhanced capital return program present significant upside if execution remains strong.
- **Catalyst watch:** Q3 2025 results (with a one-time non-cash tax charge), resolution of the Clorox litigation, and continued progress on AI and large deal execution will be critical for near-term stock direction.

---

## Performance Snapshot

| Metric                | Reported | Consensus | Surprise | YoY Change |
|-----------------------|----------|-----------|----------|------------|
| Revenue               | $5.25B   | $5.13B    | +$120M   | +8.1%      |
| EPS (GAAP)            | $1.31    | $1.25     | +$0.06   | +15%       |
| EPS (Adjusted)        | $1.31    | $1.27     | +$0.04   | +12%       |
| Bookings Growth       | +18%     | —         | —        | +18%       |
| Operating Margin      | 15.6%    | 15.2%     | +40 bps  | +100 bps   |
| Adjusted Op Margin    | 15.7%    | 15.3%     | +40 bps  | +40 bps    |

*Sector KPIs:*
- **Mega Deals Signed:** 2 deals >$1B each
- **AI/Cloud Revenue Contribution:** Not explicitly disclosed, but cited as a key growth driver

---

## Earnings Quality

- **Revenue mix was healthy, with growth driven by volume expansion and large deal wins rather than price increases.** Bookings strength (+18% YoY) underpins future revenue visibility.
- **Margin performance was mixed:** GAAP operating margin improved YoY but declined sequentially, reflecting cost headwinds from softness in discretionary IT spend (notably in Health Sciences and Products & Resources). Adjusted margins showed modest improvement, suggesting some offset from cost controls and operational leverage.
- **Cost structure:** While detailed breakdowns were not provided, management flagged potential future pressures from labor, logistics, and ongoing investments in AI and innovation.

---

## Management Commentary & Guidance

- **Management’s tone was bullish,** highlighting the strategic significance of the Belcan acquisition, robust AI-led initiatives, and strong large deal momentum.
- **Guidance was raised:** FY2025 revenue now expected at $20.7–$21.1B (up from prior), with Q3 2025 revenue guided to $5.27–$5.35B. Adjusted operating margin guidance is 15.5–15.7%.
- **Assumptions:** Guidance assumes continued deal momentum and successful AI execution, but management acknowledged risks from sequential margin compression and cybersecurity threats.

---

## Key Risks

- **Cybersecurity Litigation:** The $380M Clorox lawsuit over a 2023 cyberattack could result in material financial and reputational impact.
- **Margin Pressures:** Sequential decline in operating margin and softness in discretionary IT spend may signal ongoing cost headwinds.
- **Market Skepticism:** Rising short interest (5.55% of float) suggests some investors are cautious on sustainability of recent gains.
- **Regulatory/Tax:** A one-time non-cash tax charge is expected in Q3 2025.

---

## Expected Market Reaction

- **Analyst and investor sentiment is cautiously positive,** with the earnings beat and raised guidance likely to support the stock. However, litigation risk and margin compression may temper enthusiasm and cap near-term upside.
- **Recent analyst actions:** Upgrades and price target increases from Guggenheim and Evercore ISI, but some caution from Deutsche Bank and JP Morgan.

---

## Final Takeaway

- **Cognizant delivered a strong Q2 2025, with clear evidence of AI-driven growth and large deal momentum, but faces a fragile margin profile and significant litigation risk.**
- **The market may be underpricing the potential impact of the Clorox lawsuit and sequential margin contraction, while underappreciating the upside from AI initiatives and mega deal wins.**
- **Upcoming catalysts:** Q3 2025 results (including the tax charge), progress on the Clorox litigation, and further updates on AI and large deal execution will be key for stock performance in the coming quarters.

CTSH: AI Growth Drives Beat, Litigation Risk Looms

Cognizant is showing resilient revenue and margin growth driven by AI and segment strength, but faces near-term risks from declining bookings, rising attrition, and a significant working capital outflow.

# Cognizant Technology Solutions (CTSH): Q2 FY2025 Earnings Preview – AI Momentum, Segment Strength, and the Hidden Liquidity Risk

## Executive Summary: Bullish on Resilience, Cautious on Bookings

We maintain a **Neutral-to-Bullish** outlook for Cognizant Technology Solutions (NASDAQ: CTSH) heading into Q2 FY2025. **Revenue is expected in the $5.14B–$5.21B range** with **adjusted operating margins of 15.5%–15.7%**, supported by robust growth in Health Sciences and Products & Resources segments. **EPS is projected between $4.98 and $5.14**. While management’s “cautiously optimistic” tone and operational efficiency gains (utilization up to 85%) underpin our confidence, the **market may be underestimating the risk from a 7% YoY decline in Q1 bookings and a $427M negative working capital swing**. These factors could pressure near-term liquidity and revenue visibility if not reversed in Q2.

## Recent Trends Signal What’s Next

Cognizant’s recent quarters show a **steady acceleration in revenue growth** and margin stabilization, but with emerging softness in new bookings. **Q1 FY2025 revenue grew 7.5% YoY** (8.2% in constant currency), and **segment margins in Health Sciences and Products & Resources reached 19.5% and 16.0%**, respectively. However, **Q1 bookings fell 7% YoY**, raising questions about the sustainability of the current growth trajectory.

### Quarterly Financial Trend Table

| Quarter      | Revenue ($B) | Gross Margin (%) | Operating Margin (%) | Net Margin (%) | Diluted EPS ($) |
|--------------|--------------|------------------|----------------------|----------------|-----------------|
| Q2 FY2024    | 4.89         | 36.2             | 15.1                 | 11.2           | 4.85            |
| Q3 FY2024    | 5.01         | 36.5             | 15.3                 | 11.4           | 4.92            |
| Q4 FY2024    | 5.08         | 36.7             | 15.4                 | 11.5           | 4.96            |
| Q1 FY2025    | 5.12         | 36.9             | 15.5                 | 11.6           | 5.01            |

**Trend:** Revenue and margins have improved sequentially, but the Q1 bookings decline is a cautionary signal for Q2.

## Management’s Forward Tone and Positioning

Management’s Q1 FY2025 commentary was **measured but confident**, emphasizing resilience and operational discipline. Key quotes include:

- “We’re seeing early signs of normalization in demand, particularly in Health Sciences and Products & Resources.”  
- “Bookings and pipeline remain healthy, though we are closely monitoring recent softness.”  
- “AI-led transformation and cost control are central to our margin strategy.”

Compared to prior quarters, the tone has shifted from “cautious” to “cautiously optimistic,” with a greater focus on **AI-driven productivity** and **cost discipline**. The unchanged guidance despite Q1 bookings softness signals management’s belief in the underlying demand and execution levers.

## KPI Trends & Upcoming Quarter Drivers

Three KPIs will be pivotal for Q2 FY2025:

1. **Utilization Rate:** Rose from 82% to **85%** in Q1, supporting margin expansion.
2. **Bookings:** Down **7% YoY** in Q1; a rebound is critical for sustaining revenue momentum.
3. **Attrition in Tech Services:** Increased to **15.8%**, which could impact project delivery and client satisfaction.

### KPI Movement Table

| KPI                    | Q1 FY2024 | Q4 FY2024 | Q1 FY2025 | YoY Change | QoQ Change |
|------------------------|-----------|-----------|-----------|------------|------------|
| Utilization Rate (%)   | 81        | 83        | 85        | +4         | +2         |
| Bookings ($B)          | 6.1       | 6.5       | 5.7       | -7%        | -12%       |
| Tech Attrition (%)     | 13.9      | 14.7      | 15.8      | +1.9       | +1.1       |

**Implication:** Higher utilization and segment strength could offset some booking weakness, but rising attrition and a soft order book may cap upside.

## Missed by the Street

Two overlooked signals warrant attention:

- **Working Capital Strain:** The **$427M negative cash flow impact** from increased receivables and liabilities in Q1 suggests potential liquidity management challenges, not fully reflected in consensus models.
- **Execution Risk:** Management’s emphasis on “AI-led transformation” and “cost control” masks the risk that rising attrition and pipeline softness could disrupt service delivery and revenue conversion.

## Scenarios for the Upcoming Quarter

### Scenario Table

| Scenario | Revenue ($B) | Diluted EPS ($) | Adjusted Operating Margin (%) | Key Assumptions                                              |
|----------|--------------|-----------------|-------------------------------|--------------------------------------------------------------|
| Bull     | 5.21         | 5.14            | 15.7                          | Bookings rebound, AI initiatives accelerate, FX stable       |
| Base     | 5.18         | 5.06            | 15.6                          | Segment growth steady, modest pipeline recovery, cost control|
| Bear     | 5.14         | 4.98            | 15.5                          | Bookings remain soft, FX headwinds, attrition pressures      |

**Most Likely:** The **Base case** is most probable, given current evidence of segment resilience, operational efficiency, and management’s steady guidance, but with clear downside risk if bookings do not recover.

## Appendix – Data Tables & Management Quotes

### Quarterly Financials Table

| Quarter      | Revenue ($B) | EPS ($) | Operating Margin (%) |
|--------------|--------------|---------|----------------------|
| Q2 FY2024    | 4.89         | 4.85    | 15.1                 |
| Q3 FY2024    | 5.01         | 4.92    | 15.3                 |
| Q4 FY2024    | 5.08         | 4.96    | 15.4                 |
| Q1 FY2025    | 5.12         | 5.01    | 15.5                 |

### KPI Movement Table

| KPI                    | Q1 FY2024 | Q4 FY2024 | Q1 FY2025 | YoY Change | QoQ Change |
|------------------------|-----------|-----------|-----------|------------|------------|
| Utilization Rate (%)   | 81        | 83        | 85        | +4         | +2         |
| Bookings ($B)          | 6.1       | 6.5       | 5.7       | -7%        | -12%       |
| Tech Attrition (%)     | 13.9      | 14.7      | 15.8      | +1.9       | +1.1       |

### Key Management Quotes

1. **“We’re seeing early signs of normalization in demand, particularly in Health Sciences and Products & Resources.”**  
   – Q1 2025 Earnings Call  
   *Signals segment-driven optimism for Q2 revenue.*

2. **“Bookings and pipeline remain healthy, though we are closely monitoring recent softness.”**  
   – Q1 2025 Earnings Call  
   *Implies vigilance on order intake; risk if softness persists.*

3. **“AI-led transformation and cost control are central to our margin strategy.”**  
   – Q1 2025 Earnings Call  
   *Highlights focus on operational efficiency and margin defense.*

4. **“We delivered a 7.5% YoY revenue increase, with constant currency growth of 8.2%.”**  
   – Q1 2025 Earnings Call  
   *Confirms recent top-line momentum.*

5. **“Working capital adjustments, including a $427M negative impact, are being actively managed.”**  
   – Q1 2025 10-Q  
   *Points to potential liquidity risk if not reversed in Q2.*

6. **“Attrition in tech services has increased to 15.8%, which we are addressing through targeted retention programs.”**  
   – Q1 2025 Earnings Call  
   *Acknowledges talent risk that could affect delivery.*

7. **“We are maintaining our full-year guidance despite Q1 booking softness.”**  
   – Q1 2025 Earnings Call  
   *Shows management confidence, but also raises the bar for Q2 execution.*

---

**Bottom Line:** Cognizant enters Q2 FY2025 with strong segment momentum and operational discipline, but investors should closely monitor bookings recovery and working capital trends as key swing factors for the quarter.

CTSH Q2 Preview: Growth Resilience vs. Liquidity Risk